Mar 8, 2021
On Jan 21, 2021, the FDA approved Cabenuva, the first once-monthly injectable HIV treatment for adults. Dr. Kelly Johnson, a fellow in infectious diseases and in sexually transmitted diseases at the University of California, San Francisco, explains the implications of this new treatment and how it affects the 1.2 million Americans living with HIV. Dr Johnson is a physician focused on HIV at San Francisco General Hospital Ward 86.
Turn on notifications to never miss an episode of Coming Together for Sexual Health.
Follow Coming Together for Sexual Health on Instagram and Twitter.